From GlobeNewswire: 2025-01-15 08:19:00

Biomerica, Inc. reported a 5% increase in total revenue for the second quarter of fiscal 2025, showing growth and cost savings. Key highlights include the direct-to-consumer launch of the inFoods® IBS test and securing three key patents for inFoods® technology to address multi-billion-dollar market opportunities.

The company’s financial highlights for the second quarter of fiscal 2025 showed a 5% increase in net sales to $1.64 million, with improved gross margins and cost-saving initiatives leading to reduced operating and net losses. Biomerica continues to focus on achieving cash flow break-even and is exploring expansion opportunities.

With gross margins rising from 21% to 27% in Q2FY2024, Biomerica made significant progress in cost management and margin enhancement during the quarter. Operating expenses decreased by 26% year-over-year to $1.43 million, reflecting efficiencies from workforce reductions and streamlined operations.

Biomerica’s liquidity and capital resources remained strong, with cash and cash equivalents at $2.37 million at the end of the second quarter. The company’s CEO, Zack Irani, highlighted the progress made in aligning operations with strategic priorities and emphasized a focus on achieving cash flow break-even in the near future.



Read more at GlobeNewswire:: Biomerica Reports Second Quarter Fiscal 2025 Financial